The endocannabinoid system and cardiometabolic risk

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Cardiovascular Risk

Background:

• Rising global obesity rates, particularly abdominal obesity, are linked to increased cardiovascular risk factors.
• These factors include elevated triglycerides, low HDL cholesterol, hypertension, and hyperglycemia, defining cardiometabolic syndrome.
• Cardiometabolic syndrome significantly increases the risk of cardiovascular disease and type 2 diabetes.

Purpose of the Study:

• To review the role of the endocannabinoid system in the development of cardiometabolic disease.
• To explore the endocannabinoid system as a potential therapeutic target for visceral obesity and insulin resistance.

Main Methods:

• Literature review of studies investigating the endocannabinoid system's involvement in energy balance.
• Analysis of research on the endocannabinoid system's impact on visceral fat accumulation and appetite regulation.
• Examination of the system's role in insulin resistance and cardiovascular risk factors.

Main Results:

• The endocannabinoid system plays a crucial role in regulating energy homeostasis and appetite.
• Overactivity of the endocannabinoid system is associated with the development and progression of obesity.
• Dysregulation of this system contributes to visceral obesity, insulin resistance, and other cardiometabolic risk factors.

Conclusions:

• The endocannabinoid system is a key player in the pathophysiology of obesity and cardiometabolic syndrome.
• Targeting the endocannabinoid system offers a promising strategy for managing visceral obesity and reducing cardiovascular risk.
• Further research into modulating this system could lead to novel therapeutic interventions for metabolic and cardiovascular diseases.